Compound ID | 3470

Triclosan

Synonym(s): Irgasan DP300, Irgacare MP

Class: Synthetic small molecule antibacterial agent

Spectrum of activity: Gram-positive  &  Gram-negative
Details of activity: Broad-spectrum activity; lipid synthesis inhibitor/ fatty acid synthesis inhibitor (FabI inhibitor)
Description: Synthetic compound; initially approved as additive for oral and skin care products
Institute where first reported: Ciba-Geigy Company, Basel, Switzerland
Year first mentioned: 1964
Highest developmental phase: Approved by FDA in 1997
Development status: Discontinued
Reason Dropped: Widespread environmental dissemination and its recalcitrant nature is thought to amplify distribution of resistance genes; long-term effects could pose health risks
Chemical structure(s):
Click here for structure editor
Molecular weight: 289.54
Iso. SMILES: C1=CC(=C(C=C1Cl)O)OC2=C(C=C(C=C2)Cl)Cl
InChI Key: XEFQLINVKFYRCS-UHFFFAOYSA-N
Can. SMILES: C1=C(C=C(C(=C1)OC2=CC=C(C=C2O)Cl)Cl)Cl
InChI: InChI=1S/C12H7Cl3O2/c13-7-1-3-11(9(15)5-7)17-12-4-2-8(14)6-10(12)16/h1-6,16H

AntibioticDB is supported by GARDP.

If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions

The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.